국내외 이슈

■ 무역전쟁 일단 봉합…지표로 시선 이동
http://news.einfomax.co.kr/news/articleView.html?idxno=4061449

■ "보잉(BA), 737 맥스 올해 안에 운항재개 포기"
https://m.news.naver.com/read.nhn?mode=LSD&mid=sec&sid1=101&oid=057&aid=0001403147

■ 아마존(AMZN)자체 택배, UPS나 페덱스에 육박
https://m.news.naver.com/read.nhn?mode=LSD&mid=sec&sid1=101&oid=009&aid=0004482494

■ 알리바바(BABA), 초당 54만건 ‘광군제’ 주문 처리한 비결은 '클라우드'
https://m.news.naver.com/read.nhn?mode=LSD&mid=sec&sid1=105&oid=366&aid=0000456831

■ 애플(AAPL) “미중 합의에 한숨 돌렸다”
https://m.news.naver.com/read.nhn?mode=LSD&mid=sec&sid1=101&oid=025&aid=0002960092

■ MLCC 기술격차 벌어지나…日무라타(6981) 선두·추격바쁜 韓삼성전기
http://m.ceoscoredaily.com/m/m_article.html?no=63472

■ “그야말로 파죽지세” 마침내 부활한 AMD의 성공기
http://www.itworld.co.kr/news/139348#csidxf30973dc3baba8f843635c9641ba0e1 

■[주목!e해외주식]메이퇀디엔핑, 공유경제 이끄는 중국판 '배민'
https://news.naver.com/main/read.nhn?mode=LSD&mid=sec&oid=018&aid=0004536918&sid1=001&lfrom=kakao

■"해외주식도 가치투자…年5% 수익 목표"
https://news.naver.com/main/read.nhn?mode=LSD&mid=sec&oid=015&aid=0004256529&sid1=001&lfrom=kakao

■해외주식 투자 이렇게 시작하세요
https://news.naver.com/main/read.nhn?mode=LSD&mid=sec&oid=008&aid=0004324402&sid1=001&lfrom=kakao

■ 벤츠·테슬라도 빌려탄다…車 성장 저무는 시대, 공유시장은 뜨겁다
https://m.biz.chosun.com/svc/article.html?contid=2019121500047&utm_source=facebook&utm_medium=sns&utm_campaign=biz&Dep0=m.facebook.com

■ 통화동보제약(600867.SH), 인슐린글라진 출시
-동사의 인슐린글라진 시장 출시가 정부의 승인을 받게 되면서 세번째 국산 인슐린글라진 제품이 시장에 출시됐으며, 이에 3세대 인슐린 바이오 시밀러 성장의 새로운 단계에 정식적으로 진입하게 됨

http://finance.sina.com.cn/stock/relnews/cn/2019-12-12/doc-iihnzhfz5429290.shtml?source=cj&dv=2

■ 강봉리튬(002460.SZ), 독일 BMW와 장기 협력 계약 체결
-동사는 2020~2024년에 독일 BMW가 지정한 배터리 또는 양극 소재 공급 업체 리튬 화공 제품을 공급하는 계약을 체결했다고 공시

http://finance.sina.com.cn/stock/relnews/cn/2019-12-12/doc-iihnzhfz5429290.shtml?source=cj&dv=2